Iowa State Bank Sells 292 Shares of Johnson & Johnson $JNJ

Iowa State Bank reduced its stake in Johnson & Johnson (NYSE:JNJ) by 0.6% during the 2nd quarter, Holdings Channel reports. The firm owned 44,800 shares of the company’s stock after selling 292 shares during the period. Johnson & Johnson makes up 1.4% of Iowa State Bank’s holdings, making the stock its 22nd biggest holding. Iowa State Bank’s holdings in Johnson & Johnson were worth $6,843,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in the stock. Highline Wealth Partners LLC raised its stake in Johnson & Johnson by 51.8% during the 1st quarter. Highline Wealth Partners LLC now owns 252 shares of the company’s stock worth $42,000 after buying an additional 86 shares during the period. Stone House Investment Management LLC acquired a new stake in Johnson & Johnson during the 1st quarter worth $47,000. 1248 Management LLC acquired a new stake in Johnson & Johnson during the 1st quarter worth $48,000. von Borstel & Associates Inc. acquired a new stake in Johnson & Johnson during the 1st quarter worth $49,000. Finally, Harvest Fund Management Co. Ltd acquired a new stake in Johnson & Johnson during the 1st quarter worth $52,000. 69.55% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, EVP Jennifer L. Taubert sold 56,471 shares of Johnson & Johnson stock in a transaction dated Thursday, September 4th. The stock was sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the completion of the transaction, the executive vice president owned 178,013 shares in the company, valued at approximately $31,652,491.53. This trade represents a 24.08% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 0.16% of the company’s stock.

Johnson & Johnson Price Performance

Shares of NYSE JNJ opened at $188.95 on Wednesday. The stock has a market capitalization of $455.06 billion, a price-to-earnings ratio of 20.21, a PEG ratio of 2.40 and a beta of 0.40. The business has a 50-day moving average of $177.04 and a 200-day moving average of $163.18. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $189.92.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, beating the consensus estimate of $2.68 by $0.09. The company had revenue of $23.74 billion during the quarter, compared to analysts’ expectations of $22.85 billion. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.Johnson & Johnson’s revenue for the quarter was up 5.8% compared to the same quarter last year. During the same quarter last year, the company earned $2.82 EPS. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. As a group, sell-side analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th were issued a dividend of $1.30 per share. The ex-dividend date was Tuesday, August 26th. This represents a $5.20 dividend on an annualized basis and a yield of 2.8%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 55.61%.

Wall Street Analyst Weigh In

Several brokerages recently commented on JNJ. Guggenheim raised Johnson & Johnson from a “neutral” rating to a “buy” rating and raised their price objective for the stock from $167.00 to $206.00 in a research note on Tuesday, September 23rd. Citigroup increased their target price on Johnson & Johnson from $200.00 to $213.00 and gave the stock a “buy” rating in a report on Tuesday. Barclays increased their target price on Johnson & Johnson from $165.00 to $176.00 and gave the stock an “equal weight” rating in a report on Thursday, July 17th. UBS Group set a $198.00 target price on Johnson & Johnson in a report on Friday. Finally, Royal Bank Of Canada increased their target price on Johnson & Johnson from $181.00 to $185.00 and gave the stock an “outperform” rating in a report on Thursday, July 17th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating and nine have issued a Hold rating to the stock. According to MarketBeat, Johnson & Johnson has an average rating of “Moderate Buy” and an average price target of $189.88.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.